Christopher Jepson1, Jesse Y Hsu2, Michael J Fischer3, John W Kusek4, James P Lash5, Ana C Ricardo5, Jeffrey R Schelling6, Harold I Feldman2. 1. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA. Electronic address: cjepson@pennmedicine.upenn.edu. 2. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA. 3. Department of Medicine, University of Illinois College of Medicine, Chicago, IL; Center of Innovation for Complex Chronic Healthcare, Edward Hines Jr VA Hospital, Hines, and Jesse Brown VAMC, Chicago, IL. 4. Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. 5. Department of Medicine, University of Illinois College of Medicine, Chicago, IL. 6. Division of Nephrology and Hypertension, Case Western Reserve University, Cleveland, OH.
Abstract
RATIONALE & OBJECTIVE: Few studies have examined incident type 2 diabetes mellitus (T2DM) in chronic kidney disease (CKD). Our objective was to examine rates of and risk factors for T2DM in CKD, using several alternative measures of glycemic control. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 1,713 participants with reduced glomerular filtration rates and without diabetes at baseline, enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study. PREDICTORS: Measures of kidney function and damage, fasting blood glucose, hemoglobin A1c (HbA1c), HOMA-IR (homeostatic model assessment of insulin resistance), demographics, family history of diabetes mellitus (DM), smoking status, medication use, systolic blood pressure, triglyceride level, high-density lipoprotein cholesterol level, body mass index, and physical activity. OUTCOME: Incident T2DM (defined as fasting blood glucose ≥ 126mg/dL or prescription of insulin or oral hypoglycemic agents). ANALYTICAL APPROACH: Concordance between fasting blood glucose and HbA1c levels was assessed using κ. Cause-specific hazards modeling, treating death and end-stage kidney disease as competing events, was used to predict incident T2DM. RESULTS: Overall T2DM incidence rate was 17.81 cases/1,000 person-years. Concordance between fasting blood glucose and HbA1c levels was low (κ for categorical versions of fasting blood glucose and HbA1c = 13%). Unadjusted associations of measures of kidney function and damage with incident T2DM were nonsignificant (P ≥ 0.4). In multivariable models, T2DM was significantly associated with fasting blood glucose level (P = 0.002) and family history of DM (P = 0.03). The adjusted association of HOMA-IR with T2DM was comparable to that of fasting blood glucose level; the association of HbA1c level was nonsignificant (P ≥ 0.1). Harrell's C for the models ranged from 0.62 to 0.68. LIMITATIONS: Limited number of outcome events; predictors limited to measures taken at baseline. CONCLUSIONS: The T2DM incidence rate among individuals with CKD is markedly higher than in the general population, supporting the need for greater vigilance in this population. Measures of glycemic control and family history of DM were independently associated with incident T2DM.
RATIONALE & OBJECTIVE: Few studies have examined incident type 2 diabetes mellitus (T2DM) in chronic kidney disease (CKD). Our objective was to examine rates of and risk factors for T2DM in CKD, using several alternative measures of glycemic control. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 1,713 participants with reduced glomerular filtration rates and without diabetes at baseline, enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study. PREDICTORS: Measures of kidney function and damage, fasting blood glucose, hemoglobin A1c (HbA1c), HOMA-IR (homeostatic model assessment of insulin resistance), demographics, family history of diabetes mellitus (DM), smoking status, medication use, systolic blood pressure, triglyceride level, high-density lipoprotein cholesterol level, body mass index, and physical activity. OUTCOME: Incident T2DM (defined as fasting blood glucose ≥ 126mg/dL or prescription of insulin or oral hypoglycemic agents). ANALYTICAL APPROACH: Concordance between fasting blood glucose and HbA1c levels was assessed using κ. Cause-specific hazards modeling, treating death and end-stage kidney disease as competing events, was used to predict incident T2DM. RESULTS: Overall T2DM incidence rate was 17.81 cases/1,000 person-years. Concordance between fasting blood glucose and HbA1c levels was low (κ for categorical versions of fasting blood glucose and HbA1c = 13%). Unadjusted associations of measures of kidney function and damage with incident T2DM were nonsignificant (P ≥ 0.4). In multivariable models, T2DM was significantly associated with fasting blood glucose level (P = 0.002) and family history of DM (P = 0.03). The adjusted association of HOMA-IR with T2DM was comparable to that of fasting blood glucose level; the association of HbA1c level was nonsignificant (P ≥ 0.1). Harrell's C for the models ranged from 0.62 to 0.68. LIMITATIONS: Limited number of outcome events; predictors limited to measures taken at baseline. CONCLUSIONS: The T2DM incidence rate among individuals with CKD is markedly higher than in the general population, supporting the need for greater vigilance in this population. Measures of glycemic control and family history of DM were independently associated with incident T2DM.
Authors: J E Shaw; P Z Zimmet; A M Hodge; M de Courten; G K Dowse; P Chitson; J Tuomilehto; K G Alberti Journal: Diabetes Care Date: 2000-01 Impact factor: 19.112
Authors: Wieke H Heideman; Barend J C Middelkoop; Vera Nierkens; Karien Stronks; Arnoud P Verhoeff; Suzanne C M van Esch; Frank J Snoek Journal: Prim Care Diabetes Date: 2011-07-18 Impact factor: 2.459
Authors: Amanda Hyre Anderson; Wei Yang; Chi-yuan Hsu; Marshall M Joffe; Mary B Leonard; Dawei Xie; Jing Chen; Tom Greene; Bernard G Jaar; Patricia Kao; John W Kusek; J Richard Landis; James P Lash; Raymond R Townsend; Matthew R Weir; Harold I Feldman Journal: Am J Kidney Dis Date: 2012-06-02 Impact factor: 8.860
Authors: Yan Chen; Leila R Zelnick; Ke Wang; Ronit Katz; Andrew N Hoofnagle; Jessica O Becker; Chi-Yuan Hsu; Alan S Go; Harold I Feldman; Rupal C Mehta; James P Lash; Sushrut S Waikar; L Hamm; Jing Chen; Tariq Shafi; Bryan R Kestenbaum Journal: Nephrol Dial Transplant Date: 2020-11-17 Impact factor: 5.992
Authors: Sarah J Schrauben; Christopher Jepson; Jesse Y Hsu; F Perry Wilson; Xiaoming Zhang; James P Lash; Bruce M Robinson; Raymond R Townsend; Jing Chen; Leon Fogelfeld; Patricia Kao; J Richard Landis; Daniel J Rader; L Lee Hamm; Amanda H Anderson; Harold I Feldman Journal: BMC Nephrol Date: 2019-02-20 Impact factor: 2.388
Authors: Joseph Stavas; Guido Filler; Deepak Jain; John Ludlow; Joydeep Basu; Richard Payne; Emily Butler; Maria Díaz-González de Ferris; Tim Bertram Journal: Kidney Int Rep Date: 2022-04-21